SCHEMBL10247217

SCHEMBL10247217

O=C(Cn1ccnc1)NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.62
CYP19A1 P11511 3/20 0.57
ALDH1A1 P00352 2/20 0.56
QPCT Q16769 2/20 0.55
MAPT P10636 2/20 0.54
GAA P10253 1/20 0.54
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP11B1 P15538 1/20 0.53
CYP11B2 P19099 1/20 0.53
TBXAS1 P24557 1/20 0.53
CYP4Z1 Q86W10 1/20 0.53
QPCTL Q9NXS2 1/20 0.53
MAPK14 Q16539 1/20 0.52
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
HMOX2 P30519 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL411425 0.99 SMN1; SMN2 (0.61) SMN1; SMN2CYP19A1ALDH1A1QPCTMAPT
SCHEMBL15190312 0.86 HPGD (0.69) SMN1; SMN2CYP19A1QPCTGAAPOLB
SCHEMBL284240 0.81 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1QPCTMAPTGAA
SCHEMBL7530193 0.81 HPGD (0.71) SMN1; SMN2GAAPOLBHPGDTSHR
SCHEMBL21076446 0.79 MGLL (0.62) CYP19A1ALDH1A1QPCTHMOX2
SCHEMBL7562480 0.78 ALDH1A1 (0.54) CYP19A1ALDH1A1QPCTMAPTCYP1A2
SCHEMBL11238973 0.77 HMOX2 (0.64) CYP19A1ALDH1A1QPCTMAPTCYP1A2
SCHEMBL18546520 0.77 CYP19A1 (0.61) SMN1; SMN2CYP19A1ALDH1A1QPCTMAPT
Biphenyl SCHEMBL27824074 0.76 ALDH1A1 (0.76) CYP19A1ALDH1A1CYP11B1CYP11B2HMOX2
SCHEMBL18548047 0.76 SMN1; SMN2 (0.61) SMN1; SMN2CYP19A1ALDH1A1QPCTTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3344039-A1 SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF Arizona Board of Regents on behalf of the University of Arizona (US) 2018-07-11 EP disclosed
US-9765036-B2 Production method for producing N-benzyl-2-(2-nitro-1H-imidazol-1-yl) acetamide MINISTERIO DE EDUCACION (SV) 2017-09-19 US disclosed
WO-2017040993-A1 SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-03-09 WO disclosed
US-20160289197-A1 PRODUCTION METHOD FOR PRODUCING N-BENZYL-2-(2-NITRO-1H-IMIDAZOL-1-YL) ACETAMIDE MINISTERIO DE EDUCACIÓN (SV) 2016-10-06 US disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
WO-2008151437-A1 HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM OSTA BIOTECHNOLOGIES (CA) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System TXNRD2, HMOX1, HMOX2 SMN1; SMN2 213/4885CYP19A1 884/4885ALDH1A1 452/4885
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 SMN1; SMN2 95/4885CYP19A1 641/4885ALDH1A1 394/4885
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 SMN1; SMN2 95/4885CYP19A1 641/4885ALDH1A1 394/4885
US-20160289197-A1 PRODUCTION METHOD FOR PRODUCING N-BENZYL-2-(2-NITRO-1H-IMIDAZOL-1-YL) ACETAMIDE NAAA, NIT2, NAA15 SMN1; SMN2 617/4885CYP19A1 2105/4885ALDH1A1 1341/4885
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 SMN1; SMN2 122/4885CYP19A1 614/4885ALDH1A1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.